Abstract al-Antitrypsin (alAT) deficiency is characterized by insufficient amounts of alAT to protect the lower respiratory tract from neutrophil elastase, resulting in emphysema. Yeast-produced recombinant alAT (rAAT) has normal antielastase function but is associated with high renal clearance, thus obviating chronic intravenous administration. As an alternative, we evaluated aerosol administration of rAAT to alAT-deficient individuals. After aerosol administration of single doses of 10-200 mg of rAAT, epithelial lining fluid (ELF) alAT antineutrophil elastase defenses were augmented in proportion to the dose of rAAT administered. ELF alAT levels and antineutrophil elastase capacity 4 h after 200 mg rAAT aerosol were increased 40-fold over preaerosol levels, and were fivefold increased over baseline at 24 h after aerosol administration. rAAT was detectable in serum after aerosoL indicating that the lower respiratory tract epithelium may be permeable to rAAT, and that aerosolized rAAT is capable of gaining access to lung interstitium. No adverse clinical effects were noted. These observations demonstrate that aerosol administration of rAAT is safe and results in significant augmentation of lung antineutrophil elastase defenses, suggesting this method is a feasible approach to therapy. Because this approach is clinically unproven, further studies will be necessary to establish the longterm clinical efficacy of aerosol therapy in alAT deficiency.
Introduction
Alpha 1-antitrypsin (alAT)I deficiency is a genetic disorder characterized by low plasma and lung levels of a lAT and the development of emphysema by the third to fourth decades (1, 2) . The deficiency of alAT in the lower respiratory tract is central to the pathogenesis of the emphysema due to the critical role of a 1 AT in protecting the alveolar structures against neutrophil elastase, a broad-spectrum protease capable of de-grading all major protein components of the alveolar interstitium (1-3). As a result of the low lung levels of a I AT, neutrophil elastase released from neutrophils in the lower respiratory tract is free to attack alveolar walls, resulting in the gradual destruction of lung parenchyma and the eventual development ofemphysema (1) (2) (3) (4) . These biologic abnormalities in the lower respiratory tract can be reversed with a lAT augmentation therapy, in which human plasma-purified alAT is administered intravenously on a weekly (2, 5) or monthly (6) basis, thus reestablishing the antineutrophil elastase protective screen of the lower respiratory tract (2, 5, 6 ).
An alternative approach to therapy of a lAT deficiency is to use recombinant DNA-produced a I AT (rAAT) to augment the antineutrophil elastase screen of the alveolar structures. This approach has been made feasible by the demonstration that rAAT produced in yeast under the direction of a normal human a lAT cDNA functions as an inhibitor of neutrophil elastase in a fashion identical to that of the natural human alAT (7, 8) . However, unlike human plasma alAT, rAAT lacks carbohydrate side chains (7, 8) . As a result, when rAAT is administered intravenously it has a much shorter plasma halflife than does natural a lAT (7) . In part, this occurs because a large amount of the administered rAAT is cleared by the kidney, whereas no natural a 1 AT appears in the urine after intravenous administration (6, 7) . Compared with human plasma a 1 AT, intravenous administration of rAAT thus would require far more a 1AT to raise serum levels sufficient to protect the lung, and the large bulk of protein passing through the kidney may lead to renal disease, thus obviating this route of administration.
It may be possible, however, for rAAT to be used therapeutically to augment lung antielastase defenses if it were targeted directly to the lower respiratory tract, i.e., given by aerosol. In this regard, studies in experimental animals have demonstrated that aerosol administration permits the delivery of intact, functional rAAT to the lower respiratory tract, and that the rAAT diffuses into the alveolar interstitium, the site that must be protected in a lAT deficiency (8) . With this background, this study was designed to evaluate the feasibility of administering rAAT via aerosol to humans with a IAT deficiency.
For aerosolization of rAAT to be considered as a form of therapy for a 1 AT deficiency several criteria must be met, including (a) the rAAT must be delivered to the lower respira- (7, 8) . This rAAT preparation has a molecular mass of 45 kD, is identical to human plasma a I AT except for an additional NH2-terminal methionine and the lack ofthe three carbohydrate side chains in plasma a I AT, and functions in an identical manner as human plasma a 1AT as an inhibitor of neutrophil elastase (7, 8) . Aerosol-generating system. rAAT was aerosolized using a compressed air driven nebulizer (Mallinckrodt) selected on the basis of its ability to generate an aerosol with droplets of optimal size (< 3 ,um aerodynamic diameter) for deposition in the lower respiratory tract (8, 9) . rAAT aerosolized in this fashion retains its structure and function as an inhibitor of neutrophil elastase (8) .
Evaluation of the ability of the aerosol device to deliver aerosol to the alveolar regions was estimated to be in the range of 10-20%, estimated by quantitating the proportion of a starting dose of technetium-99-labeled diethylenetriamine pentacetic acid impacting in the lower respiratory tract after nebulization to alAT-deficient individuals.
Study population. Six Z homozygotes were entered into a preliminary study to evaluate the potential antigenicity of the rAAT (see below). These individuals (five males, one female, average age 46 ± 11 yr) were typical ofa 1AT deficiency with emphysema and a 1AT serum levels of 4.3±0.4 yM (all alAT levels are presented in micromolar units using a true laboratory a lAT standard) (2) . All data are presented as mean±SEM and all statistical comparisons were made using the two-tailed t test.
The study population used for administration of the aerosol of rAAT consisted of 16 alAT-deficient individuals (10 men, 6 women; 39±2 yr). There were 14 Z homozygotes (alAT serum levels 4.5±0.5 MAM) and 2 NUlgranile falls homozygotes (aIAT levels 0), verified by measurement of serum a 1 AT levels, isoelectric focusing of serum, family studies, and genotyping using specific oligonucleotide probes (10, 11). 5 individuals were lifelong nonsmokers, 10 were exsmokers (1 1±2 pack-yr), and 1 was a present smoker (13 pack-yr). All had evidence of mild-to-moderate emphysema, based on physical examination, chest x ray, xenon-133 ventilation scans, technetium-99m-labeled macroaggregated albumin scans and lung function (vital capacity 100±15% predicted, total lung capacity 111±12% predicted, forced expiratory volume in 1 s [FEV-1] 78±28% predicted, and diffusing capacity for carbon monoxide 86±25% predicted [corrected for hemoglobin and volume]) (12) . Resting arterial blood gases showed Po, 87±12 Torr, Pco2 37±3 Torr, and pH 7.40±0.03. Individuals with severe emphysema were excluded from the study because ofthe inability to use bronchoalveolar lavage to study the effect of aerosol.
Study design. Before administering rAAT by aerosol, a preliminary investigation was carried out to determine the safety of administration ofrAAT to a I AT-deficient individuals. Over a 6-mo period, rAAT was administered subcutaneously to six Z homozygotes. Three individuals received 1 mg and three individuals received 10 mg at biweekly intervals over a 10-wk period. Immunologic assessment included skin prick and intradermal tests to detect immediate or delayed hypersensitivity reactions, blood lymphocyte blastogenesis to yeast protein extract or to rAAT, measurement of specific antiyeast, anti-rAAT, and antihuman a 1 AT antibodies in serum, and quantification of serum a1 AT levels. There were biweekly assessments of serum chemistries, complete blood counts, erythrocyte sedimentation rate, coagulation profile, urinalysis, creatinine clearance, chest x rays, and lung function studies.
The aerosol study was designed to evaluate the biologic parameters relevant to the rAAT after a single-dose aerosol administration of rAAT. The study was done in two phases. First, escalating single doses of rAAT were administered by aerosol to alAT-deficient individuals (10 mg, n = 2; 50 mg, n = 2; 100 mg, n = 5; and 200 mg, n = 4). Second, an additional three individuals were evaluated at the 200-mg dose to determine the time dependency of biologic parameters in the lower respiratory tract modified by aerosol. For both phases of the study, before aerosol administration of rAAT, a baseline bronchoalveolar lavage was performed (2) to determine epithelial lining fluid (ELF) levels of aIAT and antineutrophil elastase capacity. The lavage procedure was repeated 4 or 24 h after aerosol to assess the effect of rAAT aerosol administration of ELF a1AT levels and antineutrophil elastase capacity.
To evaluate whether rAAT administered by aerosol diffused across the lower respiratory tract and reached the blood, we capitalized on the knowledge that the two Nullgranite falls homozygotes had no a 1 AT in the serum (13) , and thus any a IAT that was detectable must have come from the aerosolized rAAT. The Nullganite falls individuals were treated with a single dose of aerosolized rAAT and serum samples were taken at 4, 8, 24 and 48 h after the aerosol and evaluated for a lAT by ELISA (2) .
Serum was obtained preaerosol, 2 and 4 wk after aerosol administration for measurement of antibodies against rAAT, yeast, and plasma alAT. Subcutaneous and intradermal skin testing for hypersensitivity to rAAT or yeast proteins was performed preaerosol and 4 wk after aerosol administration. At multiple times in the 48 h after each aerosol administration, serum chemistries, complete blood counts, and clotting studies were evaluated. The status of the lungs was evaluated by chest x ray, pulmonary function tests, and arterial blood gases, obtained preaerosol, 4 h, 1 d, and 1 mo after aerosol administration.
To evaluate epithelial lining fluid for the presence and form of rAAT after aerosol administration, Western blot analysis of 50-fold concentrated bronchoalveolar lavage fluid was carried out by lyophilizing the fluid, reconstituting with H20, and dialyzing against phosphate buffered saline, pH 7.5. Samples were evaluated by 7.5% SDS-PAGE and Western analysis with a polyclonal anti-a 1AT antibody (8) .
Measurement of ELF a1 AT levels was done in quadruplicate by ELISA (2) and referenced to the volume of ELF as determined by the urea method (14) . To verify that the a I AT measured by ELISA represented intact rAAT, Superose-12 molecular sieve chromatographic analysis of concentrated lavage fluid of a Z homozygote was carried out after aerosolization of 200 mg rAAT. The l-ml fractions of the 100-ml column eluate were individually assayed for aIAT by ELISA.
Determination of the antineutrophil elastase capacity of ELF was performed as previously described (2) using a titrated neutrophil elastase standard. To demonstrate the ability of rAAT present in ELF after aerosol to combine with neutrophil elastase, samples of ELF derived from lyophilized bronchoalveolar lavage fluid from a Nullgranite falls homozygote were incubated (5 min, 25°C) with human neutrophil elastase (30 AM). The samples were then applied to a 7.5% SDS polyacrylamide gel and transferred to nitrocellulose for Western blotting.
Results
Initial safety assessment. The 6-mo skin-testing evaluation of rAAT suggested that the rAAT would not be recognized by the immune system as foreign. Despite biweekly "immunization" with rAAT, no abnormal clinical or immunologic parameters were observed, leading to the conclusion that it was safe to proceed with aerosolization of rAAT. Dose dependency. Administration of varying amounts of rAAT to alAT-deficient individuals resulted in a dose-response relationship for both the quantity of a 1AT present in the lower respiratory tract and the neutrophil elastase inhibitory capacity of ELF. Aerosol administration of single doses of 10, 50, 100, or 200 mg rAAT resulted in progressive augmentation of total ELF a I AT levels (preaerosol compared with the 24-h postaerosol level after administration of 200 mg rAAT, P < 0.01) (Fig. 1 A) . Not only were total ELF alAT levels increased, but the ability ofthe ELF to inhibit neutrophil elastase was also increased after rAAT aerosol (preaerosol compared with 24 h after aerosol administration of 200 mg rAAT, P < 0.01) (Fig. 1 B) . Expression of a lAT levels and antineutrophil elastase capacity relative to the concentration of albumin in lavage fluid yielded the same results: preaerosol, Structure ofthe rAA T delivered by aerosol. Analysis of lavage fluid demonstrated that the rAAT delivered by aerosol to the lower respiratory tract remained intact during the delivery process. As demonstrated by Western blot analysis of concentrated lavage fluid obtained from a Z homozygous individual 24 h after aerosol administration of 200 mg rAAT, administration of rAAT via the aerosol route resulted in clearly detectable amounts of intact rAAT in lower respiratory tract ELF (Fig. 2) . Using SDS acrylamide electrophoresis and a polyclonal antibody that recognizes both human plasma a lAT and rAAT, plasma alAT with its molecular mass of 52 kD (lane 1), is distinguishable by the difference in mass from rAAT, with a molecular mass of 45 kD (lane 2). Before aerosol administration of rAAT, the ELF contained only the expected endogenous 52 kD a 1 AT (lane 3). In contrast, after aerosol administration of rAAT, ELF contained both the 52-kD endogenous plasma alAT and the 45-kD rAAT (lane 4). The rAAT present in the ELF was intact, and looked identical to the rAAT standard that had not been aerosolized, i.e., the protein did not undergo fragmentation or was otherwise reduced in size either during aerosol or once deposited in the lung. Furthermore, consistent with the ELISA data, comparison of the relative intensity of the endogenous a lAT and rAAT on the SDS gels suggested that even 24 h after delivery, 200 mg aerosol administration of rAAT provides more a 1AT to the epithelial surface than does the endogenous a lAT of the alAT deficient individual. Additional evidence that recovered rAAT was not fragmented was provided by chromatography of the concentrated lavage fluid; evaluation of all fractions by al AT-specific ELISA demonstrated all a I AT (endogenous plus rAAT) in the 42-55-kD range.
Time dependency. Evaluation of ELF levels of a lAT at different times after a single aerosol dose of rAAT demonstrated a time dependent change in the amount of a lAT in ELF (Fig. 3) . Analysis of lavage fluid obtained 4 h after 200 mg rAAT aerosol showed that the ELF levels of a IAT were elevated > 40-fold over preaerosol ELF a IAT levels (P < 0.01). By 24 h, the ELF a I AT levels had fallen, but were still fivefold over preaerosol levels (P < 0.01). When viewed in the context of the ELF levels of a lAT in normals, single-dose administration of 200 mg rAAT normalized ELF a I AT levels in a I AT- (Fig. 4, lane 1) mg rAAT demonstrated the presence of both uncomplexed rAAT (45 kD) and rAAT at a higher molecular mass (66 kD), suggesting but not proving, that the rAAT delivered to the lower respiratory tract by aerosol may have combined with neutrophil elastase in vivo (lane 4). Moreover, consistent with the observed enhancement of ELF antineutrophil elastase capacity by the aerosol administration of rAAT, the further addition of neutrophil elastase in vitro demonstrated that the uncomplexed 45 kD rAAT present in postaerosol ELF was still functionally active and retained its ability to combine with and form the 66-kD (and to a lesser extent the 50-kD) complex of rAAT-neutrophil elastase (lane 5).
Permeability of the lower respiratory tract to aerosolized rAA T. To determine if the lung epithelial surface is permeable to aerosolized rAAT, the serum of two homozygous Nullgranite falls individuals was evaluated for the presence of a 1 AT before, and at intervals over a 48-h period after aerosol administration of 200 mg rAAT. By definition, consistent with the null status of the study individuals, no a 1AT was present in serum preaerosol. However, after aerosol administration, rAAT was detectable in serum in one individual at 8 h after aerosolization and in both patients at 24 h after aerosol (Fig.   5) . By 48 h, rAAT was not detectable in the serum of either individual. rAAT that reached the lung epithelial surface via aerosol thus was able to pass across the lower respiratory tract Figure 5 . Serum alAT levels in two homozygous Null granite falls individuals before and after aerosol administration of rAAT. rAAT (200 mg) was administered by aerosol and serum was obtained before aerosol and at intervals after aerosol and assayed for a I AT by ELISA. The limit of sensitivity of the immunoassay for a 1AT in serum is 3 nM. Each individual is represented by a separate symbol (o, *).
epithelium and enter the circulation, i.e., the lower respiratory tract epithelium is permeable to rAAT deposited on the alveolar surface by aerosol, suggesting at least some of the rAAT must have reached the alveolar interstitial tissues.
Safety. No adverse reaction was noted among any of the patients receiving rAAT by aerosol. Each aerosol administration was well tolerated and no immediate or late symptoms were noted. No clinical laboratory parameters were significantly changed at 4, 24, or 48 h or 1 mo after aerosol, when compared with the preaerosol values (data not shown). Furthermore, there was no evidence of inflammation developing in the lower respiratory tract as assessed by comparison of the bronchoalveolar lavage fluid cellular constituents of pre-and postaerosol lavage fluid; preaerosol, 21±14 X 106 total cells recovered, 83±10% macrophages, 12±9% lymphocytes, 4±4% neutrophils; postaerosol, 16±13 X 106 total cells, 85±16% macrophages, 9±9% lymphocytes, 5±4% neutrophils (P > 0.5 pre-vs. postaerosol, all comparisons). Importantly, aerosol administration of rAAT did not result in development of immunologic sensitization against rAAT. In this regard, skin testing with prick and subcutaneous injection of rAAT, yeast extract, and human a1 AT did not demonstrate a positive reaction in any individual before or after aerosol administration of rAAT and no study individual developed serum antibodies to rAAT, yeast extract, or human a 1AT.
Discussion
This study demonstrates that aerosol administration of rAAT is a feasible and effective method of augmenting the antielastase defenses of the lower respiratory tract in a IAT deficiency. By using an appropriately designed aerosol-generating system, significant quantities of intact, functional rAAT can be deposited directly on the alveolar epithelial surface, resulting not only in increased a lAT levels and antineutrophil elastase capacity in ELF, but also, due to the permeability of the alveolar epithelium to rAAT, increased levels of rAAT in lung interstitial tissues as well. Administration of rAAT results in dose-and time-dependent changes in ELF a lAT and antineutrophil elastase levels in a manner that suggests that once or twice daily aerosol administration of rAAT should result in sustained levels of antielastase protection to the lower respiratory tract. When interpreted in view of the safety of its administration, as evidenced by the lack of pulmonary, immunologic, or general clinical adverse effect of either single-dose or chronic administration of rAAT, aerosol rAAT administration may constitute a reasonable approach to therapy for alAT deficiency.
Because the lung has only a limited capacity to produce its own antineutrophil elastase protective screen, the lower respiratory tract is dependent on antielastases produced outside of the lung, principally alAT (3, 16) . The vast majority ofalAT is produced in the liver by hepatocytes and reaches the lung via the circulation; in the normal individual, sufficient alAT diffuses from plasma into the lung to inhibit the burden of elastase to which the lung is exposed (1, 3, 5, 11) . This same concept of augmenting lower respiratory tract antielastase defenses is used in intravenous augmentation therapy for a 1 AT deficiency, in which plasma purified alAT is administered intravenously and passively reaches the lung via diffusion from the circulation (2, 5, 6) . Using doses of 60 mg/kg per wk, intravenous therapy delivers sufficient aIAT to the lungs to reverse the imbalance between elastase and antielastase at the alveolar surface, where the concentration of a 1 AT in ELF is -10% the concentration in plasma (2) . In reaching the alveolar epithelial surface, the infused alAT passes through capillary endothelium, lung interstitium, and finally the alveolar epithelial membrane, in the process providing elastase protection throughout the lung, including the lung interstitium, the critical site requiring protection from elastolytic degradation.
In contrast, aerosol administration uses the opposite approach to augmenting lung antielastase defenses. Once the aerosolized rAAT passes the upper airway anatomic barriers, the first lower respiratory tract tissue reached by aerosolized rAAT is the alveolar epithelium (8) . After alveolar deposition, rAAT must traverse through lung tissues in the reverse order traveled by intravenously administered a 1 AT, moving first through the alveolar epithelium, lung interstitium, and capillary endothelium, ultimately reaching the general circulation. Aerosol administration represents a potentially far more efficient method of delivering rAAT to the alveolar surface than intravenous therapy. In this regard, 4 h after the 200-mg aerosol dose, the ELF a IAT level was -9 ,uM. It has been estimated that the total lung ELF volume is -100 ml, so that a total of 40 mg rAAT, or 20% of the initial dose, is present in ELF. This compares with an efficiency rate of only 2% for the delivery of infused a1AT to the lower respiratory tract (2) Second, studies in sheep, in which it is possible to directly sample lung interstitial lymph, have shown that after rAAT aerosol administration, rAAT is present in lymph draining the lung interstitium, as well as in blood plasma, with an -10-fold difference in concentration between lung interstitial lymph and plasma, indicating that passage of rAAT into lung interstitium and lymphatics does occur to a significant degree (8) . Although rAAT and plasma alAT may have different pharmacokinetics in the lung because of their different structure, these observations are also consistent with studies of aerosolization of plasma a 1 AT to dogs, showing alveolar deposition and retention for as long as 6 h after aerosol (19) , and aerosolization to sheep demonstrating passage of plasma a lAT into the pulmonary interstitium (20) . Although it is not possible to quantify the amounts of rAAT reaching lung interstitium after aerosol to humans, nor is it known what levels of a 1AT are present in the interstitium of normal individuals, it is nonetheless clear that the aerosol route does result in delivery of some rAAT throughout the lower respiratory tract.
Aerosol therapy may represent a significant step in reducing the cost of chronic augmentation therapy for a lAT deficiency. Although the costs of the aerosol delivery system and the drug itself cannot be accurately predicted at this time, the major savings for this form of therapy is likely to be in the amount of drug required, because the single greatest cost of augmentation therapy is the cost of the drug itself. Because for a typical 70-kg individual the amount of drug required is reduced from 4,200 mg/wk (for intravenous therapy) to an estimated 1,400 mg/wk (for aerosol therapy), a reduction by twothirds in the amount of drug needed is possible.
In this context, this investigation is an important first step in demonstrating that aerosolization of rAAT may constitute effective therapy for alAT deficiency. With the background knowledge that it is possible to safely administer plasma a I AT to humans twice daily by aerosol (20) , and with the safety and biologic efficacy of this study, it is reasonable to justify a study of the chronic administration of rAAT to humans with a I AT deficiency.
